And thank you for joining us for Marine Products Corporation’s Third Quarter 2024 Financial Earnings Conference Call. Today’s call will be hosted by Ben Palmer, President and CEO; and Mike Schmit, ...
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
Opinion
Zacks.com on MSN1hOpinion
5 Biotech Stocks Likely to Outperform as Industry Prospects Look BrightIt has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...
Despite advancements in gene-editing technologies such as CRISPR, ensuring these modifications only impact desired tissues or ...
What keeps some immune systems youthful and effective in warding off age-related diseases? In new research done on mice, scientists point the finger at a small subset of blood stem cells, which make ...
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia ...
Find Latest News, Videos and Pictures about CRISPR. Explore latest updates, news, information from NewsBytes. All about CRISPR.
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback